Novo Nordisk Donates License For Small-Molecule Compound Library To China, WHO
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Denmark-based Novo Nordisk will donate a license to its small molecule compound library to China's National Center for Drug Screening, the company announced April 28 in Copenhagen.
You may also be interested in...
Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China, Biopharma Center
$400 million facility is Novo’s largest offshore investment.
Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center
BEIJING - The Danish-headquartered biopharmaceutical outfit Novo Nordisk is building a massive, $400 million insulin plant in the Chinese east coast city of Tianjin to serve diabetes patients across China and Asia, according to company executives and government officials
Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center
BEIJING - The Danish-headquartered biopharmaceutical outfit Novo Nordisk is building a massive, $400 million insulin plant in the Chinese east coast city of Tianjin to serve diabetes patients across China and Asia, according to company executives and government officials
Need a specific report? 1000+ reports available
Buy Reports